Adaptive Biotechnologies Corporation (ADPT) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Adaptive Biotechnologies Corporation (ADPT) Healthcare & Pipeline Overview

Adaptive Biotechnologies Corporation is a commercial-stage biotechnology firm leveraging its proprietary immune medicine platform for disease diagnosis and treatment. Specializing in immunosequencing products like immunoSEQ and clonoSEQ, the company targets life sciences research, clinical diagnostics, and drug discovery, supported by key collaborations in oncology and early disease detection.

What Is the Investment Thesis for ADPT?

Adaptive Biotechnologies Corporation presents a unique investment profile centered on its proprietary immune medicine platform, which underpins both diagnostic and therapeutic applications. The company's commercial-stage products, particularly clonoSEQ for minimal residual disease monitoring in hematologic malignancies, represent a tangible revenue stream within a growing oncology diagnostics market. Strategic collaborations with industry leaders like Genentech for neoantigen T-cell therapies and Microsoft for early disease detection are significant catalysts, offering long-term growth potential by expanding into high-value therapeutic and broad diagnostic markets. While the company currently operates at a loss, evidenced by a -16.8% profit margin and -24.0% ROE, its positive free cash flow of $0.01 billion indicates some operational efficiency. The high Beta of 2.30 suggests significant volatility, and a D/E ratio of 92.84 highlights reliance on debt. The investment thesis hinges on the successful clinical progression of its pipeline, expansion of existing product indications, and the realization of value from its strategic partnerships, positioning Adaptive to capitalize on the increasing demand for precision medicine and immunotherapeutics.

Based on FMP financials and quantitative analysis

ADPT Key Highlights

• Market Capitalization: $2.03 billion, reflecting its valuation as a commercial-stage biotechnology firm focused on immune medicine.
• Gross Margin: 43.7%, indicating a solid margin on its products and services before accounting for operating expenses.
• Profit Margin: -16.8%, demonstrating that the company is currently operating at a loss, which is common for biotech firms in intensive R&D and growth phases.
• Return on Equity (ROE): -24.0%, further emphasizing current unprofitability relative to shareholder equity, consistent with its negative profit margin.
• Debt-to-Equity (D/E) Ratio: 92.84, indicating a notable reliance on debt financing relative to equity, which can influence financial flexibility.
• Free Cash Flow (FCF): $0.01 billion, showing a positive, albeit small, generation of cash after capital expenditures, suggesting some operational cash generation.

Who Are ADPT's Competitors?

ADPT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ADPT's Key Strengths?

• Proprietary and advanced immune medicine platform with diverse applications.
• Established commercial products like clonoSEQ with regulatory approvals for specific cancer indications.
• Strong strategic collaborations with industry leaders such as Genentech and Microsoft, enhancing R&D and market potential.
• Diverse product pipeline addressing life sciences research, clinical diagnostics, and drug discovery.
• Expertise in immunosequencing provides a competitive edge in precision medicine.

What Are ADPT's Weaknesses?

• Currently unprofitable, with a negative profit margin of -16.8% and ROE of -24.0%.
• High stock price volatility, indicated by a Beta of 2.30, which may deter risk-averse investors.
• Significant debt-to-equity ratio of 92.84, potentially limiting financial flexibility.
• Reliance on continued R&D success and clinical trial outcomes for pipeline products to achieve profitability.
• Burn rate associated with ongoing research and development activities.

What Could Drive ADPT Stock Higher?

• Potential expansion of clonoSEQ's approved indications for minimal residual disease monitoring in additional lymphoid cancers, broadening its market reach.
• Progress in the strategic collaboration with Genentech for the development and commercialization of neoantigen-directed T-cell therapies for various cancers, potentially leading to clinical milestones.
• Continued development and validation efforts with Microsoft Corporation for novel diagnostic tests aimed at the early detection of a wide range of diseases from a single blood sample.
• Publication of new research data or clinical study results demonstrating the utility and efficacy of the immunoSEQ platform in translational research and drug discovery applications.

What Are the Key Risks for ADPT?

• Negative return on equity (-24.0%) — the business is not currently generating profit on shareholder capital.
• Significant operating losses and a negative profit margin of -16.8%, indicating a continued need for substantial investment without current profitability.
• High stock price volatility, as evidenced by a Beta of 2.30, which could lead to substantial fluctuations in investor returns.
• High debt-to-equity ratio of 92.84, which may limit financial flexibility and increase sensitivity to interest rate changes.
• Intense competition within the biotechnology and diagnostics sectors, potentially impacting market share and pricing power for its products.
• Regulatory challenges and the need for ongoing approvals for new diagnostic indications or therapeutic developments, which can be lengthy and uncertain.

What Are the Growth Opportunities for ADPT?

• Expansion of clonoSEQ Indications: clonoSEQ is currently approved for detecting and monitoring minimal residual disease (MRD) in multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia. Expanding its CLIA-validated laboratory developed test (LDT) status to cover additional lymphoid cancers or securing FDA approval for new indications would significantly broaden its addressable market. The global MRD testing market is projected to grow substantially, driven by the increasing adoption of personalized medicine and the need for highly sensitive disease monitoring. This expansion could capture a larger share of the oncology diagnostics market, providing a clear pathway for increased revenue in the medium to long term.
• Leveraging Microsoft Collaboration for Early Disease Detection: The strategic partnership with Microsoft Corporation is focused on developing diagnostic tests for the early detection of various diseases from a single blood test. This initiative targets a massive potential market in preventative healthcare and early intervention across a wide range of conditions beyond oncology, including autoimmune and infectious diseases. Successful development and commercialization of such broad-spectrum early detection tests could unlock substantial, recurring revenue streams from a vast patient population globally. The timeline for such groundbreaking development is long-term, but the potential impact is transformative for the company.
• Advancement of Genentech Collaboration in Neoantigen T-cell Therapies: The collaboration with Genentech, Inc. is centered on the development, manufacture, and commercialization of neoantigen-directed T-cell therapies for the treatment of a range of cancers. This partnership represents Adaptive's strategic move beyond diagnostics into the high-value therapeutic segment of the oncology market. The global oncology therapeutics market is one of the largest and fastest-growing sectors in healthcare, driven by unmet medical needs. Successful progression of these T-cell therapies through clinical trials and eventual commercialization could provide significant, long-term revenue streams and establish Adaptive as a key player in innovative cancer treatments.
• Growth in Life Sciences Research and Drug Discovery Applications: The immunoSEQ platform serves as a core immunosequencing product for translational research, enabling the discovery of new prognostic and diagnostic signals. Continued adoption of immunoSEQ by academic institutions, pharmaceutical companies, and contract research organizations for their drug discovery and development projects will drive recurring revenue. The global market for genomics and proteomics research tools is expanding as R&D spending in the life sciences sector increases. Adaptive's platform offers unique insights into the adaptive immune system, making it an invaluable tool for researchers and drug developers seeking to understand and manipulate immune responses.
• International Market Expansion: While the company's headquarters are in Seattle, US, the provided data does not explicitly detail its global geographic reach. The nature of Adaptive's advanced diagnostic and research platforms, particularly clonoSEQ, suggests significant potential for international market expansion. Entering new global markets, especially in regions with developing healthcare infrastructures and increasing demand for precision diagnostics and advanced research tools, could unlock substantial untapped revenue streams. This would involve navigating diverse regulatory landscapes but offers a pathway to diversify revenue sources and reduce reliance on a single geographic market over the long term.

What Opportunities Does ADPT Have?

• Expansion of clonoSEQ's approved indications for minimal residual disease monitoring into additional lymphoid cancers.
• Development of groundbreaking early disease detection tests through the collaboration with Microsoft Corporation.
• Progression and commercialization of neoantigen-directed T-cell therapies in partnership with Genentech.
• Potential for international market expansion to increase global adoption of its diagnostic and research platforms.
• Increasing demand for precision medicine and personalized diagnostics in oncology and other therapeutic areas.

What Threats Does ADPT Face?

• Intense competition from other biotechnology and diagnostic companies with similar or alternative technologies.
• Significant regulatory hurdles and lengthy approval processes for new diagnostic products and therapeutic candidates.
• Potential for technological obsolescence if competing platforms emerge with superior capabilities.
• Reliance on successful clinical trials for pipeline products, with high failure rates inherent in drug development.
• Intellectual property challenges and the need to continuously protect its proprietary technologies.

What Are ADPT's Competitive Advantages?

• Proprietary immune medicine platform and advanced immunosequencing technology, providing unique insights into the adaptive immune system.
• Established commercial clinical diagnostic products like clonoSEQ, which has regulatory approvals for specific indications.
• Strategic collaborations with industry leaders such as Genentech and Microsoft, offering access to significant R&D resources, market reach, and validation.
• Extensive database and expertise in T-cell and B-cell receptor sequencing data, creating a knowledge barrier for competitors.
• First-mover advantage and specialized expertise in specific immunosequencing applications and minimal residual disease diagnostics.

What Does ADPT Do?

Adaptive Biotechnologies Corporation, incorporated in 2009 and headquartered in Seattle, Washington, is a commercial-stage company dedicated to developing an advanced immune medicine platform for the diagnosis and treatment of a wide array of diseases. Initially known as Adaptive TCR Corporation, the company rebranded in December 2011, signifying its broader ambitions in the biotechnology space. At its core, Adaptive offers immunoSEQ, a sophisticated immunosequencing platform that serves as a foundational tool for answering translational research questions and discovering novel prognostic and diagnostic biomarkers. This platform is critical for advancing scientific understanding in immunology. Beyond research, Adaptive provides clinical diagnostic products such as T-Detect COVID, designed for the reliable confirmation of past COVID-19 infection by detecting T-cell responses. A cornerstone of its clinical offerings is clonoSEQ, a highly sensitive diagnostic product utilized for the detection and monitoring of minimal residual disease (MRD) in patients suffering from multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia. clonoSEQ is also available as a CLIA-validated laboratory developed test for other lymphoid cancers, underscoring its versatility in oncology. Furthermore, the company offers immunoSEQ T-MAP COVID, a specialized tool for vaccine developers and researchers to accurately measure the T-cell immune response to various vaccines. Adaptive Biotechnologies extends its reach into drug discovery and therapeutic development through a robust pipeline of clinical products and services aimed at diagnosing, monitoring, and treating complex conditions, including cancer, autoimmune disorders, and infectious diseases. The company strategically serves three primary applications: life sciences research, clinical diagnostics, and drug discovery. Its market position is significantly bolstered by key strategic collaborations, notably with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen-directed T cell therapies for cancer, and with Microsoft Corporation, focused on pioneering diagnostic tests for the early detection of various diseases from a single blood sample. These partnerships are instrumental in expanding Adaptive's technological capabilities and market potential.

What Products and Services Does ADPT Offer?

• Develops an immune medicine platform for the diagnosis and treatment of various diseases.
• Offers immunoSEQ, a core immunosequencing product for translational research and discovering diagnostic signals.
• Provides T-Detect COVID for confirming past COVID-19 infections by detecting T-cell responses.
• Markets clonoSEQ, a clinical diagnostic for detecting and monitoring minimal residual disease in lymphoid cancers.
• Supplies immunoSEQ T-MAP COVID for vaccine developers to measure T-cell immune responses to vaccines.
• Maintains a pipeline of clinical products and services for cancer, autoimmune conditions, and infectious diseases.
• Serves life sciences research, clinical diagnostics, and drug discovery applications.
• Engages in strategic collaborations with Genentech for neoantigen T-cell therapies and Microsoft for early disease detection.

How Does ADPT Make Money?

• Generates revenue from the sale and utilization of its proprietary immunosequencing platforms and related services (e.g., immunoSEQ).
• Earns revenue from commercial clinical diagnostic products, such as clonoSEQ and T-Detect COVID, for disease detection and monitoring.
• Receives funding and potential milestone payments or royalties from strategic collaborations with pharmaceutical partners (e.g., Genentech) for therapeutic development.
• Secures revenue from partnerships focused on developing novel diagnostic tests for early disease detection (e.g., Microsoft).
• Provides CLIA-validated laboratory developed tests (LDTs) for specific cancer monitoring, offering specialized diagnostic services.

What Industry Does ADPT Operate In?

Adaptive Biotechnologies Corporation operates within the dynamic and rapidly evolving Biotechnology industry, a sub-sector of Healthcare. The company is strategically positioned at the intersection of advanced diagnostics and therapeutic development, leveraging its expertise in immunosequencing. The broader industry is characterized by significant R&D investment, a focus on precision medicine, and the increasing importance of personalized diagnostics and immunotherapies. Adaptive's core competency in analyzing the adaptive immune system aligns with major market trends towards understanding disease at a molecular level and developing targeted treatments. The competitive landscape includes established pharmaceutical companies, specialized diagnostic firms, and emerging biotech innovators. Adaptive differentiates itself through its proprietary immune medicine platform and its unique collaborations, aiming to carve out a significant niche in areas like minimal residual disease monitoring, early disease detection, and neoantigen-directed cancer therapies.

Who Are ADPT's Key Customers?

• Life sciences researchers, academic institutions, and biotechnology companies.
• Pharmaceutical companies engaged in drug discovery and development.
• Clinical oncologists and hematologists treating patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia.
• Patients requiring minimal residual disease monitoring for various lymphoid cancers.
• Vaccine developers and researchers studying immune responses.

Adaptive Biotechnologies Corporation Financial Trajectory

Adaptive Biotechnologies Corporation (ADPT) reported $70.9M in revenue for Q1 2026, a decline of 1.1% compared to the prior quarter. The company recorded a net loss of $20.0M, with diluted EPS of $-0.13. Revenue has contracted over three consecutive quarters, which investors in this mid-cap Healthcare stock should monitor closely. Across the four most recent quarters, ADPT averaged $-0.08 in diluted EPS.

Company Profile

Adaptive Biotechnologies Corporation operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Seattle, US. The company is led by CEO Chad Robins. ADPT has traded publicly since 2019.

How Adaptive Biotechnologies Corporation Is Valued

Adaptive Biotechnologies Corporation carries a market capitalization of $3.50B, placing it in the mid-cap category. Relative to its peer group, ADPT's quantitative score of 35/100 is below the peer average of 53/100.

ROE -24%Key Financial Metrics

Return on equity for Adaptive Biotechnologies Corporation stands at -24.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -5.7%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.35 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 4/9Financial Health

Adaptive Biotechnologies Corporation's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 4.80 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project Adaptive Biotechnologies Corporation revenue of about $286.6M for fiscal 2026, with EPS near $-0.46. The estimate reflects 7 contributing analysts.

ADPT Financials

ADPT Latest News

ADPT Analyst Consensus

ADPT MoonshotScore

Adaptive Biotechnologies Corporation Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources